

CUMULATIVE INDEX

Volume 33, Numbers 1-4, 1990

- Abdominal pregnancy, 438-444
- Abdominal wall trigger points in chronic pelvic pain, 145-147
- Abruptio placentae, 406-412, 434
- Acanthosis nigricans with hyperandrogenism and insulin resistance, 644-648, 657
- Acardiac twins, 28-29, 91
- Acrosclerosis, 770
- ACTH stimulation test
 - in hyperandrogenism, 642
 - in polycystic ovary syndrome, 658
- Activin, 690-701
 - biologic actions of, 694-701
 - isolation and characterization of, 692
- Acyclovir in pregnancy, 276-283
 - in herpes simplex virus infection, 254, 256, 278-281, 804
 - mechanism of action, 277
 - pharmacokinetics of, 277-278
 - in varicella-zoster virus infections, 281-283, 795
- Adenoma, pituitary, hyperprolactinemia in, 625-626
- Adhesions, pelvic, laparoscopic procedures in, 139-140, 196
- Adrenals
 - androgen production in polycystic ovary syndrome, 658-659
 - disorders with hyperandrogenism, 641
- α -Adrenergic agents
 - and regulation of gonadotropin secretion, 545
 - in urinary incontinence, 338-340
- α -Adrenergic blockers in postoperative urinary retention, 380
- β -Adrenergic agents in preterm labor, 505-506
- β -Adrenergic antagonists in urinary incontinence, 340-341
- Age
 - and inhibin levels, 700
 - maternal, and twin gestation, 6
 - and pelvic pain incidence, 129
- AIDS in pregnancy
 - placental findings in, 240
 - skin lesions in, 798-799
 - zidovudine in, 283-285, 799
- Allen-Masters syndrome, chronic pelvic pain in, 162-163, 197
- Amenorrhea, hypothalamic
 - dietary factors in, 616-617
 - exercise in, 615-616
 - management of, 617-618
- ϵ -Aminocaproic acid therapy in placental abruption, 412
- Amniocentesis
 - in preterm labor, 506-507, 508
 - in twin gestation, 46-47, 64-65
 - for pulmonary maturity, 47
- Amniotic fluid embolism, 478-480
- Amniotic sac infections, viral, 233-234
- Amniotomy in placental abruption, 410
- Amoxapine, hyperprolactinemia from, 624
- Androgens
 - antiandrogens, 574
 - generation and activity of, 563-575
 - hyperandrogenic disorders, 640-653
 - clinical categories of, 652-653
 - diagnostic and therapeutic approach to, 640-643
 - genetic causes of, 643-648
 - hyperinsulinemia in, 643-652
 - in polycystic ovary syndrome, 640, 656-659
 - and hypothalamic GnRH pulse generator regulation, 541-542
- Anemia in twin gestations, 11, 15-16, 32
- Anesthesia in labor
 - epidural, and uterine rupture, 433-434
 - in preterm labor and delivery, 509
 - in twin gestation, 57
- Aneurysms, cerebral, in pregnancy, 467-469
- Anovulation in polycystic ovary syndrome, 656
- Antibiotics in septic shock, 489
- Anticholinergic drugs in detrusor instability of bladder, 369-370
- Antidepressants, tricyclic, in detrusor instability of bladder, 371
- Antiinflammatory drugs, nonsteroidal, in dysmenorrhea, 171-173
- Anxiety, and pain tolerance, 126
- Arteriovenous malformations, cerebral, in pregnancy, 469
- Arthritis, rheumatoid, skin changes in, 772-773
- Assay methodology for hormones, 591-608
- Atony of uterus during labor, 422-423
- Atropine in detrusor instability of bladder, 369-370
- Autoimmune progesterone dermatitis in pregnancy, 738
- Azidothymidine in AIDS in pregnancy, 283-285
- Bacterial infections, and skin changes in pregnancy, 792-794
- Bed rest
 - in multifetal pregnancy, 81
 - in twin gestation, 35-36, 61-62
- Behavioral therapy in detrusor instability of bladder, 368-369
- Bichloroacetic acid in papillomavirus infection in pregnancy, 264, 809
- Biliary tract in twin gestation, 14
- Bioassays of hormones, 591-593
- Bioluminescence assays of hormones, 598-599
- Biopsy
 - cone, in cervical intraepithelial neoplasia, 832-834, 839-840
 - fine needle, in cervical cancer, 855

Biosensors for hormone assays, 604-607

Bladder

- detrusor instability, 315-316
 - management of, 367-375
- diary in urinary incontinence, 311-313
- function in urinary continence, 298-306
- neck suspension operation in urinary incontinence, 349-352
- vesicovaginal fistulas, 386-389

Blood gases, arterial, in twin gestation, 12-13

Blood pressure in twin gestation, 12

Blood transfusions. *See* Transfusion

Blood volume, and hypovolemia in obstetric hemorrhage, 454-458

Bone density, prolactin levels affecting, 627, 634

Bonnar's device in urinary incontinence, 342-343

Brain death in pregnancy, 471

Breast-feeding of twins, 106-110

Bromocriptine in hyperprolactinemia, 631-632

Bullous dermatoses in pregnancy, 746-752

Burch colposuspension in urinary incontinence, 352-353, 361

Butyrophonones, hyperprolactinemia from, 624

Calcium channel blockers

- in detrusor instability of bladder, 371-372
- in dysmenorrhea, 173
- hyperprolactinemia from, 625

Caloric requirements in twin gestation, 11-12

Candidal infection, and vulvovaginitis in pregnancy, 732

Carcinoma, cervical. *See* Cervical cancer

Cardiovascular system in twin gestation, 12-13

Cauterization in cervical intraepithelial neoplasia, 831-832

Cerclage, cervical

- in placenta previa, 419
- in twin gestation, 36, 62

Cerebral palsy, and perinatal asphyxia, 517-518

Cerebrovascular emergencies in pregnancy, 467-471

- and brain death, 471
- hemorrhagic, 467-469
- occlusive, 469-471

Cervical cancer

- adenocarcinoma, 863-869
 - treatment of, 865-868
- cervicography in, 824
- chemotherapy in, 910-914
 - intraarterial, 913
 - radiation with, 893-894
- colposcopy in, 824, 838-839
- computed tomography in, 853-854
- cone biopsy in, 832-834, 839-840
- cytologic diagnosis of, 818-824
- extraperitoneal approach to lymph nodes in, 856
- fine needle aspiration of lymph nodes in, 855
- hysterectomy in
 - compared to radiotherapy, 872-879
 - in intraepithelial neoplasia, 834-835
 - ovarian preservation in, 867, 876-877
 - and postoperative radiotherapy, 867-868, 884-885
 - and preoperative radiotherapy, 866-867
- lymph node metastasis in, 856-857, 883-887

lymphangiography in, 852-853

magnetic resonance imaging in, 854

microinvasive, 846-851

staging of, 849-850

treatment of, 850-851

in pregnancy, 837-844

intraepithelial neoplasia in, 837-840

invasive carcinoma in, 840-844

radioimmunodetection in, 854-855

radiotherapy in

altered fractionated schedules in, 891-892

compared to surgery, 872-879

drug therapy with, 893-894, 914

extended field in, 857-858

high dose-rate brachytherapy in, 889-890

hyperthermia with, 893

interstitial implants in, 890-891

neutron-beam therapy in, 892-893

new techniques in, 889-894

postoperative, 867-868, 884-885

preoperative, 866-867

recurrent, pelvic exenteration in, 897-908

low rectal anastomosis in, 903

neovagina construction in, 904

pelvic floor coverage in, 903-904

results of, 904-908

urinary conduit diversion in, 901-903

review questions, 917-918

screening for, 817-825

staging of, 852-859

in microinvasive carcinoma, 849-850

transperitoneal approach to lymph nodes in, 855-856

treatment of intraepithelial neoplasia, 826-835

cautery in, 831-832

cryotherapy in, 827-829

hysterectomy in, 834-835

laser caporization in, 829-831

ultrasonography in, 853

Cervical cerclage

in placenta previa, 419

in twin gestation, 36, 62

Cervical cultures in preterm labor, 504, 507

Cervicography in cancer detection, 824

Cesarean section

and placenta previa risk, 416-418

in preterm labor, 509

uterine rupture after, 433

Chemiluminescence assays of hormones, 599-600

Chemotherapy in cervical cancer, 910-914

radiation with, 893-894, 914

Chickenpox. *See* Varicella-zoster infection in pregnancy

Chimerism in twin gestation, 29-30

Cholestasis, intrahepatic, in pregnancy, 743

Chorionic gonadotropin, 585-587

action of, 586-587, 678-682

degradation of, 586

receptors for, 586

serum levels

in ectopic pregnancy, 440, 443, 450

in twin gestation, 8

structure, synthesis, and secretion of, 585-586

Chromosome abnormalities, and chimerism in twin gestations, 29-30

- Cimetidine, 574
hyperprolactinemia from, 624
- Cisplatin in cervical cancer, 911-914
radiation with, 894, 914
- Climacteric, urinary incontinence in, 392-397
- Clomiphene, 573
in hyperandrogenism, 643
in ovulation induction, 560
in polycystic ovary syndrome, 665
- Coagulation
changes in pregnancy, 16
defects in placental abruption, 407-408, 411-412
disseminated intravascular
in amniotic fluid embolism, 479
in septic shock, 487
- Coital frequency, and twin gestation, 7
- Collagen vascular disease in pregnancy, cutaneous manifestations of, 759-774
- Colporrhaphy, anterior, in urinary incontinence, 349
- Colposcopy
in cervical cancer detection, 824, 838-839
and cone biopsy of cervical intraepithelial neoplasia, 832-834
- Colposuspension in urinary incontinence, 342-343, 361
- Computed tomography
in cervical cancer, 853-854
in hyperprolactinemia, 628-629
- Condyloma of genital tract. *See* Papillomavirus infection in pregnancy
- Congenital anomalies in twin gestations, 33, 89-92
and single fetal demise, 69-70
ultrasonic identification of, 47
- Conization in cervical intraepithelial neoplasia, 832-834, 839-840
- Continence, urinary
disorders of. *See* Incontinence, urinary
and mobility of vesicle neck, 304
sphincteric function in, 304-306
structures involved in, 298-299, 358
supportive mechanism in, 299-304
- Contraception
intrauterine device in
dysmenorrhea from, 174
pelvic pain from, 156
oral agents in
in dysmenorrhea, 171
in hirsutism, 664
hyperprolactinemia from, 625
role in erythema nodosum, 778-780
- Cordocentesis in twin transfusion syndrome, 44-45
- Corpus luteum, 559-560, 668-686
development and function in menstrual cycle, 668-672
local control of, 675-678
pituitary control of, 672-675
dysfunction of, 682-686
embryonic control of, in early pregnancy, 678-682
- Corticosteroid therapy in preterm labor, 506, 507
- Couvellaire uterus in placental abruption, 408
- Coxsackievirus infections in pregnancy, skin lesions in, 797
- CREST syndrome, 771
- Cryoprecipitate for hypofibrinogenemia in placental abruption, 411-412
- Cryotherapy in cervical intraepithelial neoplasia, 827-829
- Cushing's disease, hyperandrogenism in, 641
- Cyproterone acetate, 574
- Cystometry, 311, 316-322
catheters in, 319
filling methods in, 319-320
media used in, 320
position in, 321
single-channel, 316-318
subtracted, 318
urethrocystometry, 318-319
- Cystoplasty, augmentation, 374
- Cystoscopy in bladder neck suspension operation, 349-352
- Cystourethroscopy, 311, 327
- Cytologic screening for cervical cancer, 818-824
- Cytomegalovirus infection in pregnancy
laboratory tests for, 221-222
placental findings in, 237-239
teratogenicity of, 246-247
- Dehydroepiandrosterone sulfate levels
in hyperandrogenism, 642
in polycystic ovary syndrome, 657
- Delivery in placental abruption, 409-410
- Depression
and chronic pelvic pain, 180-181
and pain tolerance, 126
- Dermatitis
papular, in pregnancy, 737, 742, 754-755
progesterone, autoimmune, in pregnancy, 736
- Dermatologic pathology. *See* Skin changes in pregnancy
- Dermatomyositis in pregnancy, 766-769
treatment of, 769
- Dermatoses, bullous, in pregnancy, 746-752
- Detrusor instability of bladder, 315-316
management of, 367-375
- Dexamethasone
in hirsutism, 664
in hyperandrogenism, 642, 643
- Diabetes mellitus in pregnancy, pruritis in, 744
- Diazepam in postoperative urinary retention, 380
- Dicyclomine hydrochloride in detrusor instability of bladder, 370
- Dietary factors in hypothalamic amenorrhea, 616-617
- Dilatation and curettage in chronic pelvic pain, 195-196
- Dopamine
and prolactin secretion, 587-588, 622
antidopaminergic drugs affecting, 624
as therapy in septic shock, 488
- Dopaminergic agents in regulation of gonadotropin secretion, 545-546
- Drainage of puerperal hematomas, 429
- Drugs
agents in cervical cancer management, 893-894, 910-914
and chronic pelvic pain, 132
pruritus from, 745
transdermal absorption in pregnancy, 718-726

- Dysmenorrhea, 149, 166-175
 calcium channel blockers in, 173
 clinical features of, 166-168
 electrical nerve stimulation in, transcutaneous, 174
 etiology of, 168-170
 laparoscopy in, 174
 management of, 171-175
 oral contraceptives in, 171
 primary, 166-167, 170
 management of, 171-174
 prostaglandin synthetase inhibitors in, 171-173
 secondary, 167-168, 170-171
 management of, 174-175
 Dystocia, shoulder, 526-533
- Echovirus infections in pregnancy, skin lesions in, 797
- Eclampsia, 460-465
 management of, 461-465
- Ectopic pregnancy, 448-453
 abdominal, 438-444
 diagnosis of, 450-451
 epidemiology of, 448-449
 etiology of, 449-450
 management of, 451-452
- Education, and pelvic pain incidence, 130
- Edwards pubovaginal spring in urinary incontinence, 342
- Electric stimulation
 anal or rectal, in urinary incontinence, 341-342, 360, 372-373
 transcutaneous, in dysmenorrhea, 174
- Electrical conductance, urethral, in incontinence, 328
- Electrocautery in cervical intraepithelial neoplasia, 831-832
- Electrochemical immunoassays for hormones, 604-607
- Electromyography in urinary incontinence, 327
- Embolism in pregnancy
 amniotic fluid, 478-480
 cerebral, 469-470
 pulmonary, 475
- Emepronium bromide in detrusor instability of bladder, 370
- Emergencies, obstetric
 abruptio placentae, 406-412
 acute respiratory failure, 493-500
 amniotic fluid embolism, 478-480
 cerebrovascular disease, 467-471
 deep vein thrombosis, 473-478
 eclampsia, 460-465
 ectopic pregnancy, 448-453
 abdominal, 438-444
 hemorrhagic hypovolemia, 454-458
 and intrapartum assessment of fetus, 515-524
 placenta accreta, 424-426
 placenta previa, 414-420
 postpartum hemorrhage, 422-424
 preterm labor, 502-512
 puerperal hematomas, 428-430
 pulmonary embolism, 475
 review questions, 535-536
 septic shock, 482-491
 shoulder dystocia, 526-533
 uterine inversion, 426-428
 uterine rupture, 432-436
- Endocrinology, reproductive
 corpus luteum function and dysfunction, 668-686
 hormone assay methodology, 591-608
 hyperandrogenic disorders, 640-653
 hyperprolactinemic disorders, 622-634
 hypothalamic GnRH pulse generator, 538-548
 disorders of, 611-618
 maturational changes in ovarian follicles, 551-561
 novel ovarian regulatory peptides, 690-701
 peptide hormone activity, 576-589
 polycystic ovary syndrome, 640, 655-666
 review questions, 703-704
 steroid hormone activity, 563-575
- Endometriosis
 dysmenorrhea in, 174-175
 laparoscopic procedures in, 138-139, 196
 pain in, 149-150
- Endoscopy
 in bladder neck suspension operation, 349-352
 in urinary incontinence, 327
- Enkephalins, 125
- Enterocolitis, necrotizing, in twins, 94
- Enterovirus infection in pregnancy
 laboratory tests for, 228
 placental findings in, 239-240
 skin lesions in, 797
 teratogenicity of, 249
- Enzyme-linked immunosorbent assays of hormones, 601-604
- Ephedrine in urinary incontinence, 339
- Epstein Barr virus infection in pregnancy, 797-798
 placental findings in, 239
 teratogenicity of, 247-248
- Ergot preparations in postpartum hemorrhage, 423
- Erythema
 infectiosum, in pregnancy, 794-795
 multiforme, in pregnancy, 734
 nodosum, 777-781
 association with pregnancy and female hormones, 733, 778-780
 treatment of, 780-781
- Estrogens
 antiestrogens, 572-574
 generation and activity of, 563-575
 hypoestrogenism in hyperprolactinemia, 627
 and hypothalamic GnRH pulse generator regulation, 542-545
 and luteal function in menstrual cycle, 675-676
 receptor status in disease, 574-575
 role in erythema nodosum, 778-780
 secretion in polycystic ovary syndrome, 659
 as therapy in urinary incontinence, 340-341, 360, 396
 phenylpropanolamine with, 340, 396
- Exenteration, pelvic, in recurrent cervical cancer, 897-908
- Exercise, and hypothalamic amenorrhea, 615-616
- Faradism in urinary incontinence, 334-336
- Fetocide, selective
 in multifetal pregnancy, 82-84
 in twin gestation, 74-75
- α -Fetoprotein
 in amniotic fluid in twin gestation, 47
 maternal, in twin gestation, 8

Fetus

- in abdominal pregnancy, 443
- in abruptio placentae, 409
- endotoxin affecting, 486
- heart rate monitoring, 518-522
 - in preterm labor, 503-504, 507, 508
 - in uterine rupture, 434
- intrapartum assessment of, 515-524
 - and methods of prevention and intervention, 522-524
- lung maturity assessment in twins, 47, 65-66
- malformations in twin gestation, 33, 89-90
 - and single fetal demise, 69-70
 - ultrasonis identification of, 47
- maternal rubella affecting, 796
- melanoma of, 786-787
- papryraeus, in twin gestation, 26-27, 42
- in placenta previa, 418
- Fibrinogen deficiency in placental abruption, 407-408, 411-412
- Fifth disease in pregnancy, skin lesions in, 794-795
- Fistulas, urovaginal, 382-390
- Flavoxate hydrochloride in detrusor instability of bladder, 371
- Flufenamic acid in dysmenorrhea, 173
- Fluid therapy in pregnancy
 - in acute respiratory failure, 498-500
 - in eclampsia, 465
 - in hemorrhagic hypovolemia, 457-458
 - in septic shock, 487-488
- Fluorescence immunoassays of hormones, 600-601
- 5-Fluorouracil in papillomavirus infection in pregnancy, 264-265, 809
- Folate levels in twin gestations, 11
- Follicle(s), ovarian
 - maturational changes in, 551-561
 - in polycystic ovary syndrome, 656
- Follicle-stimulating hormone, 576-581
 - action of, 581
 - and corpus luteum function, 674
 - degradation of, 578-579
 - receptors for, 579-581
 - secretion of, 577-578
 - in polycystic ovary syndrome, 660
 - regulation by inhibin, 695-698
 - structure and synthesis of, 576-577
- Folliculitis, pruritic, in pregnancy, 742-743
- Folliculogenesis abnormalities, luteal dysfunction in, 684-685
- Follistatin, 690-701
 - biologic actions of, 694-701
 - isolation and characterization of, 692-694
- Galactorrhea in hyperprolactinemia, 626
- Gastrointestinal system
 - disorders of, chronic pelvic pain in, 155
 - in twin gestation, 13-14
- Genetic factors
 - in hyperandrogenism, 643-648
 - and twin gestation, 7
- Genitourinary fistulas, 382-390
- Gingivitis in pregnancy, 715, 731
- Gonadotropin
 - human chorionic. *See* Chorionic gonadotropin
 - human menopausal, as therapy in polycystic ovary syndrome, 665

- serum levels in twin gestation, 6
- as therapy in ovulation induction, 560-561
- Gonadotropin-releasing hormone hypothalamic pulse generator, 538-548
 - α -adrenergic pathways in, 545
 - androgens affecting, 541-542
 - disorders of, 611-618
 - dopaminergic agents affecting, 545-546
 - endogenous opiates affecting, 539-541, 612-618
 - estrogens affecting, 542-545
 - in normal menstrual cycle, 546-548
 - serotoninerger pathways in, 545
- Gonorrhea in pregnancy, skin lesions in, 792-793
- Granuloma gravidarum of gingiva, 714-715, 731
- Growth retardation, intrauterine, in twins, 5, 33, 43, 88
- Hair growth in pregnancy, 715, 729-730
- Heart, septic shock affecting, 485
- Heart rate, fetal. *See* Fetus, heart rate monitoring
- Hemangiomas, cutaneous, in pregnancy, 731
- Hematomas, puerperal, 428-430
 - management of, 429
- Hemorrhage
 - intracranial, in premature infants, 94
 - in pregnancy
 - in abdominal pregnancy, 443
 - in abruptio placentae, 406-407
 - cerebrovascular, 467-469
 - hypovolemia from, 454-458
 - in placenta accreta, 424-425
 - in placenta previa, 416
 - postpartum, 422-424
 - in uterine inversion, 426
 - in uterine rupture, 435
- Heparin therapy in pregnancy
 - in cerebral arterial occlusion, 470
 - in deep vein thrombosis, 475-478
 - in placental abruption, 412
- Hepatitis B virus infection in pregnancy, laboratory tests for, 224-225
- Heroin, hyperprolactinemia from, 624
- Herpes simplex virus infection in pregnancy, 801-804
 - acyclovir in, 254, 256, 278-281, 804
 - gestationis, 734-735, 738-740, 746-749
 - laboratory tests for, 218-221
 - management of, 253-256
 - placental findings in, 239
 - teratogenicity of, 247
- Hirsutism
 - in hyperandrogenism, 641
 - in polycystic ovary syndrome, 656-657
 - treatment of, 664-665
 - in pregnancy, 715, 730
- Histamine, and prolactin secretion, 622
- H₂-histamine antagonists affecting, 624-625
- Hormone assay methodology, 591-608
 - bioassays, 591-593
 - bioluminescence, 598-599
 - biosensors in, 604-607
 - chemiluminescence, 599-600
 - enzyme-linked immunosorbent assays, 601-604
 - fluorescence immunoassays, 600-601
 - future prospects in, 604-608
 - immunoradiometric, 597-598

- radioimmunoassays, 595-598
 radioreceptor, 593-595
- Hyaline membrane disease in twins, 5, 35, 93
- Hydralazine in hypertension in pregnancy, 464
- 21-Hydroxylase deficiency, hyperandrogenism in, 642
- 17-Hydroxyprogesterone caproate, prophylactic, in twin gestation, 62
- Hydroxyurea in cervical cancer, radiation with, 893-894
- Hyperandrogenic disorders, 640-653
- Hyperprolactinemia, 622-634
- Hypersensitivity of visceral tissue, induction of, 144
- Hypertension in eclampsia, 460
 control of, 464-465
- Hyperthermia treatments with radiotherapy in cervical cancer, 893
- Hypoglycemia in twins, 94
- Hypotension in septic shock, 484-485
- Hypothalamic disorders, hyperprolactinemia in, 625
- Hypothalamic GnRH pulse generator, 538-548
 disorders of, 611-618
- Hypothermia, controlled, in neurosurgery in pregnancy, 468
- Hypothyroidism, hyperprolactinemia in, 625
- Hypovolemia in obstetric hemorrhage, 454-458
 management of, 457-458
- Hysterectomy
 in abruptio placentae, 412
 in cervical cancer
 compared to radiotherapy, 872-879
 in intraepithelial neoplasia, 834-835
 ovarian preservation in, 867, 876-877
 and postoperative radiation, 867-868, 884-885
 and preoperative radiation, 866-867
 in chronic pelvic pain, 157, 197-199, 203-207
 in placenta accreta, 425
 in uterine rupture, 436
- Ibuprofen in dysmenorrhea, 172
- Ileocystoplasty in bladder instability, 374
- Imipramine in urinary incontinence, 340, 371
- Immunodeficiency virus infection in pregnancy
 placental findings in, 240
 skin lesions in, 798-799
 zidovudine in, 283-285
- Immunoradiometric assays of hormones, 597-598
- Immunotherapy in cervical cancer, radiation with, 893-894
- Impetigo herpeticiformis in pregnancy, 735, 740-741, 751-752
- Incontinence, urinary
 α -adrenergic agonists in, 338-340
 β -adrenergic antagonists in, 340-341
 ambulatory urodynamics in, 327
 anticholinergic drugs in, 369-370
 artificial urinary sphincter in, 355-356, 363-364
 augmentation cystoplasty in, 374
 and barriers to treatment, 297
 behavioral therapy in, 368-369
 bladder denervation in, 373-374
 bladder diary in, 311-313
 bladder neck suspension in, endoscopic, 349-352
 calcium channel blockers in, 371-372
 in climacteric, 392-397
 anatomy and physiology in, 392-393
 clinical features of, 393-395
 urodynamic findings in, 395-396
 colporrhaphy in, anterior, 349
 colposuspension in, 352-353, 361
 conservative management of sphincter incompetence in, 330-344
 general measures in, 330-331
 indications for, 330
 cystometry in, 311, 316-322
 in detrusor instability, 315-316
 genuine stress incontinence with, 374-375
 management of, 367-375
 diagnostic tests in, 310-311
 drug therapy in, 338-341, 360, 369-372
 electric stimulation in, 341-342, 360, 372-373
 electromyography in, 327
 endoscopy in, 327
 estrogen therapy in, 340-341, 360, 396
 faradism in, 334-336
 genuine stress incontinence, 358-365
 detrusor instability with, 374-375
 evaluation of, 360
 mechanisms in, 358-359
 medical therapy in, 360
 surgery in, 360-365
 history taking in, 308-309
 interferential therapy in, 336
 Marshall-Marchetti-Krantz procedure in, 352, 361
 mechanical devices in, 342-344
 overflow incontinence, 378-379
 pelvic floor exercises in, 331-334, 360
 perinatal, 333-334
 stress-specific, 333
 periurethral injections in, 349, 364-365
 pessary pad test in, 327, 395
 physical examination in, 309-310
 physiotherapy in, 331-338, 360
 results of, 338
 prevalence of, 295-296
 prostaglandin synthetase inhibitors in, 372
 quantification of urine loss in, 325-328
 review questions, 399-400
 sling procedure in, 353-355, 361-363
 social impact of, 296-297
 spasmolytic agents in, 370-371
 suprapubic procedures in, 352-356
 surgery in
 causes of failure in, 359-360
 characteristics of operations in, 348
 in detrusor instability, 373-374
 in genuine stress incontinence, 360-365
 postoperative regime in, 346
 and postoperative urinary retention, 379-380
 preoperative preparation in, 347-349
 in urethral sphincter incompetence, 346-356
 tricyclic antidepressants in, 371
 ultrasonography in, 311, 327-328
 urethral electric conductance in, 328
 urethral pressure profilometry in, 311, 326-327, 396
 uroflowmetry in, 311, 325-326
 in urovaginal fistulas, 382-390
 vaginal cones in, 336-338
 vaginal procedures in, 349

CUMULATIVE INDEX

- vaginal/suprapubic procedures in, 349-352
 videocystourethrography in, 311, 322-323, 395
- Indomethacin**
 in detrusor instability of bladder, 372
 in dysmenorrhea, 172
 prophylactic, in twin gestation, 63
- Infections**
 chronic pelvic pain in, 156
 in pregnancy
 septic shock in, 482-491
 skin changes in, 792-799
- Infertility**
 luteal phase defects in, 682-685
 in polycystic ovary syndrome, 656
- Influenza virus infection in pregnancy, teratogenicity of, 249-250**
- Inhibin, 690-701**
 biologic actions of, 694-701
 isolation and characterization of, 691-692
 production by granulosa cells, 701
 regulation of production, 698-699
 and secretion of FSH, 695-698
 serum levels of
 in aging, 700
 in menstrual cycle, 699
 in pathologic states, 700-701
 in pregnancy, 699-700
- Insulin levels**
 in hyperandrogenism, 643-652
 in polycystic ovary syndrome, 660-661
- Interferential therapy in urinary incontinence, 336**
- Interferon therapy in papillomavirus infection in pregnancy, 265, 809**
- Intracranial hemorrhage in preterm infants, 94**
- Iron**
 deficiency in pregnancy, pruritus in, 744
 kinetics in pregnancy, 11
- Ischemia, cerebral, in pregnancy, 469-471**
- Johnson maneuver in uterine inversion, 427**
- Kegel pelvic floor exercises in urinary incontinence, 331-334, 360**
- Ketoprofen in dysmenorrhea, 173**
- Kidney**
 failure of
 hyperprolactinemia in, 626
 in placental abruption, 408
 in pregnancy, pruritus in, 744
 in septic shock, 486
 in twin gestation, 14-15
- Labetalol in hypertension in pregnancy, 465**
- Labor**
 assessment of fetus in, 515-524
 emergencies in. *See* Emergencies, obstetric
 in multifetal pregnancy, 84-85
 in placental abruption, 410
 preterm, 502-512
 shoulder dystocia in, 526-533
 in twin gestation, 51-57
 anesthesia in, 57
 nonvertex twin A in, 56
 special considerations in, 56
 ultrasound in, 47
 vertex twin A, nonvertex twin B in, 54-56
 vertex twin A, vertex twin B in, 53-54
- Laparoscopy**
 in chronic pelvic pain, 135-141, 196
 in adhesions, 139-140, 196
 diagnosis with, 137-138, 196
 in endometriosis, 138-139, 196
 uterine nerve ablation in, 140-141, 200
 in dysmenorrhea, 174
- Laryngeal papillomatosis, perinatal, 807-808**
- Laser therapy, carbon dioxide**
 in cervical intraepithelial neoplasia, 829-831
 in papillomavirus infection in pregnancy, 265, 809-810
- Lentigo maligna melanoma, 782**
- Levator muscles, tenderness of, 148**
- Liver**
 diseases in pregnancy, pruritus in, 744
 function in twin gestation, 14
- Lung maturity, fetal, in twin gestation, 47, 65-66**
- Lupus erythematosus in pregnancy, 732-733, 759-766**
 acute cutaneous, 764-765
 chronic cutaneous or discoid, 760-762
 subacute cutaneous, 762-764
 treatment of, 765-766
- Luteal conditions. *See* Corpus luteum**
- Luteinizing hormone, 582-585**
 action of, 585
 degradation of, 583
 midcycle surge of, 668-669
 and corpus luteum development, 672-674
 pulsatile secretion of, 538-548
 and follicular maturation, 556-557
 receptors for, 583-585
 secretion in polycystic ovary syndrome, 659-660
 serum levels in hyperandrogenism, 652, 653
 structure and synthesis of, 582-583
- Lyme disease in pregnancy, skin lesions in, 793-794**
- Lymph node metastasis in cervical cancer, 856-857, 883-887**
- Lymphangiography in cervical cancer, 852-853**
- Magnesium sulfate**
 in eclamptic convulsions, 462-464
 in preterm labor, 505
- Magnetic resonance imaging**
 in abdominal pregnancy, 440-441
 in cervical cancer, 854
 in hyperprolactinemia, 629-630
- Marshall-Marchetti-Krantz procedure in urinary incontinence, 352, 361**
- Measles in pregnancy, 795-796**
- Mefenamic acid**
 in detrusor instability of bladder, 372
 in dysmenorrhea, 173
- Melanoma in pregnancy, 731-732, 782-789**
 treatment of, 787-788
- Melasma in pregnancy, 728-729**
- Membrane rupture in preterm labor, 507-508**
- Menopausal gonadotropin therapy in polycystic ovary syndrome, 665**
- Menopause, urinary incontinence in, 392-397**

- Menstrual cycle
 follicular maturation and ovulation in, 551-561
 gonadotropin-releasing hormone pulse generator in, 546-548
 in hyperandrogenism, 641
 in hyperprolactinemia, 626-627
 and hypothalamic amenorrhea, 615-618
 inhibin levels in, 699
 luteal development and function in, 668-672
 in polycystic ovary syndrome, 656
 Metabolism in twin gestation, 10-12
 Methadone, hyperprolactinemia from, 624
 Methanetheline bromide in detrusor instability of bladder, 370
 Methotrexate in placenta accreta, 426
 α -Methyl dopa, hyperprolactinemia from, 624
 Methylergonovine in postpartum hemorrhage, 423
 Metoclopramide, hyperprolactinemia from, 624
 Military status, and pelvic pain incidence, 130-131
 Misonidazole in cervical cancer, radiation with, 894
 MMP1 tests in chronic pelvic pain, 178-179, 181-185, 207-208
 Molluscum fibrosum gravidarum, 715, 731
 Mononucleosis, infectious, in pregnancy, 797-798
 Morphine, hyperprolactinemia from, 624
 Mortality, fetal, in twin gestation, 4-5, 35
 Multifetal pregnancy, 78-85
 antepartum management of, 81-82
 delivery in, 84-85
 delivery room resuscitation in, 92-93
 diagnosis of, 79
 incidence of, 78-79
 natural history of, 79-81
 placentas in, 25-26
 preterm labor in, 509-510
 prevention of, 85
 selective reduction in, 82-84
 twinning in. *See* Twin gestation
 Mumps virus infection in pregnancy, teratogenicity of, 250
 Myofascial pain, pelvic, 147-148, 154
 Nail growth in pregnancy, 715, 730
 Naloxone, and luteinizing hormone secretion, 539, 612
 Naltrexone
 in hypothalamic amenorrhea, 617
 and luteinizing hormone secretion, 539
 Naproxen in dysmenorrhea, 172
 Necrotizing enterocolitis in twins, 94
 Nerve supply of pelvic viscera, 119-125
 Neurectomy, presacral, in chronic pelvic pain, 199-200
 Neurologic disorders
 and cerebrovascular emergencies in pregnancy, 467-471
 in twins, 5-6
 Neuropeptides, 125-126
 Nervi, pigmented, in pregnancy, 731
 Nifedipine
 in detrusor instability of bladder, 371
 in dysmenorrhea, 173
 Nutrition
 and caloric requirements in twin gestations, 11-12
 and twin gestation, 6-7
 Obesity
 in polycystic ovary syndrome, 657
 and urinary incontinence, 330
 Opiates, endogenous, and hypothalamic GnRH pulse generator regulation, 539-541, 612-618
 Ovary
 corpus luteum function and dysfunction, 668-686
 follicular maturational changes, 551-561
 functional cysts of, chronic pelvic pain in, 196-197
 hyperandrogenism, 640-653
 novel regulatory peptides, 690-701
 polycystic ovary syndrome, 640, 655-666
 hyperandrogenism in, 640, 656-659
 preservation in hysterectomy for cervical cancer, 867, 876-877
 steroid hormone activity, 563-575
 Ovulation
 induction of, 618
 clomiphene or gonadotropins in, 560-561
 and multifetal pregnancies, 7, 78-79, 98
 in polycystic ovary syndrome, 665
 mechanisms in, 558-559
 Oxybutynin in detrusor instability of bladder, 371
 Oxygen
 consumption in twin gestation, 13
 therapy in pregnancy
 in acute respiratory failure, 497
 in septic shock, 489
 Oxytocin
 in abruptio placentae, 410
 in placenta accreta, 426
 in postpartum hemorrhage, 423
 uterine rupture from, 433
 Pain
 cortical perception of, 126
 pelvic. *See* Pelvic pain, chronic
 referred, 118-119
 with hyperesthesia and tenderness, 144-145
 without tenderness, 144
 in uterine rupture, 435
 visceral, compared to somatic pain, 117-119
 Pap smears in cervical cancer detection, 818-824
 Papillomatosis, laryngeal, perinatal, 807-808
 Papillomavirus infection in pregnancy, 258-266, 732, 804-810
 laboratory tests for, 227-228
 and laryngeal papillomatosis, 807-808
 maternal and fetal considerations in, 259-260
 natural history of, 258-259
 transmission to fetus, 260-263, 807
 treatment of, 263-266, 808-810
 Papular dermatitis of pregnancy, 737, 742, 754-755
 Parasitic infections in pregnancy, pruritus in, 744-745
 Parity
 and twin gestation, 6
 and uterine rupture, 433
 Parvovirus B19 infection in pregnancy, 268-274
 clinical features of, 269
 epidemiology of, 269-270
 fetal effects of, 270-272
 laboratory tests for, 226-227
 pathology of, 272-274
 skin lesions in, 794-795

- Pelvic exenteration in recurrent cervical cancer, 897-908
- Pelvic floor exercises in urinary incontinence, 331-334, 360
- Pelvic pain, chronic
- abdominal wall trigger points in, 145-147
 - age factors in, 129-130
 - in Allen-Masters syndrome, 162-163, 197
 - atypical functional, 154-155
 - clinical evaluation of, 152-153
 - current understanding of, 163-164
 - demographics of, 129-133
 - in depression, 180-181
 - dilatation and curettage in, 195-196
 - in dysmenorrhea, 149, 166-175
 - and educational status, 130
 - in endometriosis, 149-150
 - epidemiology of, 128-129
 - in gastroenterologic disorders, 155
 - hysterectomy in, 157, 197-199, 203-207
 - in infections, 156
 - laparoscopy in, 135-141, 196
 - and medical history, 132
 - mesial visceral pain in, 148-150
 - and military status, 130-131
 - multidisciplinary approach in, 203-209
 - myofascial, 147-148, 154
 - neuroanatomy of, 119-125
 - neuropharmacology of, 125-126
 - neurophysiology of, 117-119
 - occult somatic pathology in, 152-158
 - in ovarian functional cysts, 196-197
 - in ovarian remnant syndrome, 200
 - in posttraumatic stress disorders, 179-180, 185-187
 - presacral neurectomy in, 199-200
 - psychogenic, 136, 177-191
 - psychological testing in, 178-180, 207-208
 - psychotherapy in, 187-191
 - racial distribution of, 130
 - and reproductive history, 131-132
 - and results of MMPI, 181-185
 - in retrodisplacement of uterus, 159-160
 - review questions, 210
 - sexual history in, 133, 179
 - surgery in, 194-201
 - tissue sensitization and referral in, 144-145
 - unusual etiologies of, 157
 - in urologic pathology, 155-156
 - uterine nerve ablation in, 140-141, 200
 - vaginal, 148-149
 - in vascular congestion, 156-157, 160-162, 197
 - in vestibule, 148
- Pemphigus vulgaris in pregnancy, 749-751
- Peptide hormone activity, 576-589
- chorionic gonadotropin, 585-587
 - follicle-stimulating hormone, 576-581
 - luteinizing hormone, 582-585
 - prolactin, 587-589
- Pereyra procedure in urinary incontinence, 349, 350, 361
- Perineometers, vaginal, 332
- Pessary pad test in urinary incontinence, 327, 395
- Phenothiazines, hyperprolactinemia from, 624
- Phenoxybenzamine in postoperative urinary retention, 380
- Phenylpropanolamine in urinary incontinence, 339-340
- estrogens with, 340, 396
- Physiotherapy in urinary incontinence, 331-338, 360
- results of, 338
- Pigmentation of skin
- in pregnancy, 716-717, 728
 - in scleroderma, 770
- Piroxicam in dysmenorrhea, 173
- Pituitary gland
- adenomas of, hyperprolactinemia in, 625-626
 - treatment of, 630-634
 - in control of luteal function, 672-675
- Placenta
- abruption of, 406-412
 - management of, 408-412
 - in uterine rupture, 434
 - accreta, 424-426
 - management of, 425-426
 - hyperplacentosis with pruritus, 743
 - increta, 424
 - management in abdominal pregnancy, 442-443
 - melanoma metastasis to, 786
 - percreta, 424
 - previa, 414-420
 - management of, 418-420
 - in twin gestation, 18-30
 - diamniotic, dichorionic twin placenta in, 19-21
 - diamniotic, monochorionic twin placenta in, 23-24
 - monoamniotic, monochlorionic twin placenta in, 24-25
 - monochorionic twin placenta in, 21-23
 - and ultrasonographic prediction of amnionity and chorionity, 45-46
 - viral infections affecting, 232-240
- Placental lactogen levels, maternal, in twin gestation, 8, 10
- Plethysmography, impedance, in deep vein thrombosis in pregnancy, 474
- Pneumonia, varicella, in pregnancy, 283
- Podophyllin in papillomavirus infection in pregnancy, 264, 808
- Polyarteritis nodosa in pregnancy, 773-774
- Polycystic ovary syndrome, 655-666
- clinical features of, 656-657
 - diagnosis of, 663-664
 - endocrinology of, 657-661
 - heterogeneity of, 662-663
 - hyperandrogenism in, 640, 656-659
 - inhibin levels in, 700-701
 - pathophysiology of, 661-662
 - treatment of, 664-666
- Polycythemia vera in pregnancy, pruritus in, 744
- Polyhydramnios in twin gestation, 33
- Polymyositis in pregnancy, 766-769
- treatment of, 769
- Polytomography, sellar, in hyperprolactinemia, 628
- Postpartum period, hemorrhage in, 422-424
- Posttraumatic stress disorders, and chronic pelvic pain, 179-180, 185-187
- Preeclampsia, 460
- in twin gestation, 32-33

CUMULATIVE INDEX

- Pregnancy**
 cervical cancer in, 837-844
 ectopic, 448-453
 abdominal, 438-444
 embryonic control of luteal function in, 678-682
 emergencies in. *See* Emergencies, obstetric
 inhibin levels in, 699-700
 skin changes in, 713-717, 728-737
 transdermal drug absorption in, 718-726
 virus diseases in. *See* Virus infections in pregnancy
 Premature rupture of membranes in twin gestation, 34
 Preterm labor, 502-512
 advanced, management of, 508-509
 intact membranes in, 503-507
 in multiple gestation, 81, 509-510
 neonatal morbidity and mortality in, 510-511
 in placenta previa, 418
 ruptured membranes in, 507-508
 and transfer of patients, 510
 in twin gestation, 34, 60-66, 93-94
 early diagnosis of, 60
 prevention of, 61-64
 treatment of, 64
Progesterone
 and autoimmune dermatitis in pregnancy, 736
 and luteal function in menstrual cycle, 676-677
 prophylactic therapy in twin gestation, 62
 receptor status in disease, 574-575
Progestins
 generation and activity of, 563-575
 secretion in polycystic ovary syndrome, 659
 as therapy in polycystic ovary syndrome, 666
Prolactin, 587-589
 action of, 589
 and corpus luteum function, 674-675
 degradation of, 588
 hyperprolactinemia, 622-634
 clinical features of, 626-627
 diagnosis of, 627-630
 pathologic conditions associated with, 625-626
 pharmacologic, 624-625
 physiologic, 623-624
 in polycystic ovary syndrome, 661
 treatment of, 630-634
 receptors for, 588-589
 serum levels in hyperandrogenism, 653
 structure, synthesis, and secretion of, 587-588
Propantheline bromide in detrusor instability of bladder, 370
Prostaglandin(s)
 and luteal function in menstrual cycle, 677-678
 serum levels in dysmenorrhea, 168-169
 therapy with
 in postoperative urinary retention, 380
 in postpartum hemorrhage, 423-424
Prostaglandin synthetase inhibitors
 in detrusor instability of bladder, 372
 in dysmenorrhea, 171-173
Prurigo
 annularis, in pregnancy, 736
 gestationis, 737, 742, 752, 754
Pruritus in pregnancy, 735-736, 738-745
 drug-related, 745
 in folliculitis, 742-743
 in herpes gestationis, 734-735, 738-740
 and hyperplacentosis, 743
 in impetigo herpetiformis, 735, 740-741
 in intrahepatic cholestasis, 743
 localized, 744
 in papular dermatitis, 737, 742
 in prurigo gestationis, 737, 742
 psychogenic, 745
 as symptom of systemic disease, 744-745
 urticarial papules and plaques in, 736, 741-742, 755-758
Psychogenic conditions
 chronic pelvic pain, 136, 177-191
 pruritus in pregnancy, 745
Psychological aspects
 of twin gestations, 35
 of urinary incontinence, 296
Psychological testing in chronic pelvic pain, 178-180, 207-208
 and results of MMPI, 181-185
Psychotherapy
 in chronic pelvic pain, 187-191
 in dysmenorrhea, 173
Pulmonary embolism in pregnancy, 475
Pulmonary function in twin gestation, 13
Quadruplet gestations. *See* Multifetal pregnancy
Race, and pelvic pain incidence, 129
Radioimmunoassays of hormones, 595-598
Radioimmunodetection of cervical cancer, 854-855
Radiology of skull in hyperprolactinemia, 628
Radioreceptor assays of hormones, 593-595
Radiotherapy in cervical cancer
 compared to surgery, 872-879
 extended field in, 857-858
 new techniques in, 889-894
 postoperative, 867-868, 884-885
 preoperative, 866-867
Raynaud's phenomenon in atherosclerosis, 770
Raz procedure in urinary incontinence, 349-350, 361
Referred pain, 118-119
 with hyperesthesia and tenderness, 144-145
 without tenderness, 144
Reserpine, hyperprolactinemia from, 624
Respiratory distress syndrome, adult, in pregnancy, 493-500
 in septic shock, 485-486
 treatment of, 495-500
Respiratory system
 disease in twins, 5, 35, 93
 in twin gestation, 13
Rheumatoid arthritis, skin changes in, 772-773
Ritodrine in preterm labor, 505
Ru-486, 574
Rubella virus infection in pregnancy, 796-797
 laboratory tests for, 225-226
 placental findings in, 236-237
 teratogenicity of, 244-246
Rubeola in pregnancy, 795-796
Rupture
 of membranes in preterm labor, 507-508
 of uterus, 432-436
Sacrococcygeal teratoma in twin gestation, 29
Scleroderma in pregnancy, 760-772
 treatment of, 772

CUMULATIVE INDEX

- Screening for cervical cancer, 817-825
- Sebaceous glands in pregnancy, 715-716
- Seizures in eclampsia, 460
control of, 462-464
- Septic shock in pregnancy, 482-491
clinical features of, 484-487
management of, 487-491
- Serotonergic pathways in regulation of gonadotropin secretion, 545
- Sexual history, and chronic pelvic pain, 133, 179
- Shock
in placental abruption, 407
septic, in pregnancy, 482-491
- Shoulder dystocia, 526-533
management of, 530-533
- Skin changes in pregnancy, 713-717, 728-737
in AIDS, 798-799
in bacterial infections, 792-794
bullous dermatoses in, 746-752
in collagen vascular diseases, 759-774
in dermatomyositis, 766-769
in enterovirus infections, 797
in erythema infectiosum, 794-795
in erythema nodosum, 777-781
in genital herpes, 801-804
in gonorrhea, 792-793
hair growth in, 715, 729-730
hyperpigmentation in, 716-717, 728
in lupus erythematosus, 732-733, 759-766
in Lyme disease, 793-794
in measles, 795-796
in melanoma, 782-789
molluscum fibrosum gravidarum in, 715, 731
in mononucleosis, 797-798
nail growth in, 715, 730
in papillomavirus infections, 804-810
papular dermatoses in, 737, 742, 754-758
in polyarteritis nodosa, 773-774
prurigo gestationis in, 737, 742, 753
pruritus in, 735-736, 738-745
review questions, 813-814
in rheumatoid arthritis, 772-773
in rubella, 796-797
in scleroderma, 760-772
striae gravidarum in, 716, 730
sweat and sebaceous glands in, 715-716
and transdermal drug absorption, 718
tumors in, 714-715
in varicella, 795
vascular, 713-714, 730-732
in viral infections, 794-799
- Slings procedures in urinary incontinence, 353-355, 361-363
- Spasmolytic agents in detrusor instability of bladder, 370-371
- Spironolactone, 574
in hirsutism, 664
- Stamey procedure in urinary incontinence, 349, 350, 361
- Steroid hormones
biosynthesis and activity of, 563-575
receptors for, 569-572
- Stress incontinence, genuine, 358-365
- Striae gravidarum, 716, 730
- Substance P, 125
- Sulpiride, hyperprolactinemia from, 624
- Surgery. *See also* Cesarean section; Hysterectomy
in chronic pelvic pain, 157, 194-201
followed by chronic pelvic pain, 134
neurosurgery in pregnancy, 468
in prolactinomas, 632
in septic shock, 490
in urinary incontinence, 346-349
causes of failure in, 359-360
in detrusor instability, 373-374
in genuine stress incontinence, 360-365
and postoperative urinary retention, 379-380
in urethral sphincter incompetence, 346-356
urovaginal fistulas from, 382-383
- Sweat glands in pregnancy, 715-716
- Tamoxifen, 573-574
- Tampons in urinary incontinence, 342
- Telogen effluvium, postpartum, 715, 729-730
- Teratogenicity of virus infections in pregnancy, 242-250
embryologic concepts in, 243-244
pathophysiology in, 244
- Teratoma, sacrococcygeal, in twin gestation, 29
- Terbutaline in preterm labor, 505
- Terodiline hydrochloride in detrusor instability of bladder, 371-372
- Thieberge-Wiessenbach syndrome, 771
- Thioxanthenes, hyperprolactinemia from, 624
- Thrombosis in pregnancy
cerebral venous, 470-471
deep vein, 473-478
treatment of, 475-478
pelvic vein, septic, 490
- Thyroid disease in pregnancy, pruritus in, 744
- Thyrotropin-releasing hormone, and prolactin secretion, 587, 622-623
- Tocolysis
in abruptio placentae, 409
in placenta previa, 419
in preterm labor, 504-506, 507
prophylactic, in twin gestation, 36, 62-63
- Tolfenamic acid in dysmenorrhea, 173
- Toxicemic rash of pregnancy, 737, 754
- Transfusion
in abruptio placentae, 410, 412
in obstetric hemorrhagic hypovolemia, 457-458
in placenta previa, 418-419
in puerperal hematomas, 429
in uterine rupture, 435
- Transfusion syndrome in twin gestation, 27-28, 44-45, 72-73, 91-92, 94-95
- Trichloroacetic acid in papillomavirus infection in pregnancy, 264, 809
- Trichomonal vulvovaginitis in pregnancy, 732
- Tricyclic antidepressants, hyperprolactinemia from, 625
- Trigger points
abdominal wall, 145-147
myofascial, 147-148
- Triplet gestations. *See* Multifetal pregnancy
- Tumor necrosis factor, and septic shock, 484
- Tumors
cervical cancer, 815. *See also* Cervical cancer
in pregnancy
cutaneous, 731-732

CUMULATIVE INDEX

- gingival, 714-715
pruritus in, 745
- Twin gestation**
acardiac fetus in, 28-29, 91
amniocentesis in, 46-47, 64-65
 for pulmonary maturity, 47
antepartum management of, 32-37
assessment of fetal well-being in, 35
bed rest in, 35-36, 61-62
chimerism in, 29-30
coital frequency affecting, 7
complications of, 32-35
congenital anomalies in, 33, 89-92
conjoined twins in, 90, 96
delayed-interval delivery in, 36-37
delivery room resuscitation in, 92-93
developmental outcome in, 97-98
diagnosis of, 7-9
dizygotic, 3, 18
early diagnosis of, 60-61
etiology of, 3-4
family adjustment to, 102
and feeding of infants, 106-111
 bottle-feeding in, 110-111
 breast-feeding in, 106-110
fertility agents affecting, 7, 98
and fetus papyraceus, 26-27, 42
genetic factors in, 7
and growth in childhood, 96-97
hyaline membrane disease in, 5, 35, 93
hypoglycemia in, 94
incidence of, 4, 87
intracranial hemorrhage in, 94
intrapartum management of, 51-57
 ultrasound in, 47
intrauterine growth retardation in, 5, 33, 43, 88
maternal age in, 6
maternal size affecting, 7
monitoring of uterine activity in, 63-64
monozygotic, 3, 18
morbidity in, 5-6, 34-35
mortality in, 4-5, 34, 87-88
neonatal depression in, 5
neurologic disorders in, 5-6
nutrition affecting, 6-7
and parenting concerns, 102-106
parity affecting, 6
physiologic adaptation to, 10-16
 cardiovascular, 12-13
 gastrointestinal, 13-14
 hematologic, 15-16
 metabolic, 10-12
 renal, 14-15
 respiratory, 13
 uterine, 15
placenta in, 18-30
preterm labor in, 93-94
prophylactic cerclage in, 36, 62
prophylactic indomethacin in, 63
prophylactic tocolytics in, 36, 62-63
psychological problems with, 35
pulmonary maturity in, 47, 65-66
review questions, 113
and sacrococcygeal teratoma, 29
single fetal demise in, 26-29, 33, 68-75, 90-91
incidence of, 68-69
management of, 71-72
and morbidity in surviving twin, 95-96
selective fetocide in, 74-75
structural defects in, 69-70
special considerations in, 56, 87-98
transfusion syndrome in, 27-28, 44-45, 72-73, 91-92, 94-95
ultrasound in, 8-9, 41-42
and vanishing twin phenomenon, 26-27, 33
zygosity determination in, 70-71
- Ultrasonography**
in abdominal pregnancy, 440
in cervical cancer, 853
Doppler studies in deep vein thrombosis in pregnancy, 474
in placenta accreta, 425
in placenta previa, 415-416
in preterm labor, 504, 507
in twin gestation, 41-48
 in amniocentesis, 46-47, 65
 in diagnosis, 8-9, 41-42
 in fetal growth assessment, 42-45
 intrapartum, 47
 in prediction of amnionity and chorionity, 45-46
in urinary incontinence, 311, 327-328
- Uterovaginal fistulas, 389-390**
- Urethra**
electrical conductance test in urinary incontinence, 328
pressure profilometry, 311, 326-327, 396
sphincter incompetence, surgery in, 346-356
- Urethrocystometry, 318-319**
- Urethrovaginal fistulas, 385-386**
- Urinary incontinence. *See* Incontinence, urinary**
- Urinary retention, postoperative, 379-380**
- Urinary sphincters, artificial, 355-356, 363-364**
- Uroflowmetry, 311, 325-326**
- Urologic pathology, chronic pelvic pain in, 155-156**
- Urovaginal fistulas, 382-390**
diagnosis of, 383-384
immediate repair of, 383
prevention of, 382-383
timing of repair in, 384-385
ureterovaginal, 389-390
urethrovaginal, 385-386
vesicovaginal, 386-389
- Urticarial papules and plaques, pruritic, in pregnancy, 736, 741-742, 755-758**
- Uterine nerve ablation in chronic pelvic pain, 140-141, 200**
- Uterus**
atony during labor, 422-423
cervical cancer. *See* Cervical cancer
Couvelaire, in placental abruption, 408
inversion in labor, 426-428
 management of, 427-428
monitoring of activity in twin gestation, 63-64
retrodisplacement of, and chronic pelvic pain, 159-160
rupture in pregnancy, 432-436
 management of, 435-436
in twin gestation, 15

CUMULATIVE INDEX

- Vagina
 cones for strengthening of pelvic floor, 336-338
 pain in, 148-149
 perineometers, 332
 silastic device for urinary incontinence, 343-344
 urovaginal fistulas, 382-390
- Vanishing twin phenomenon in twin gestation, 26-27, 33
- Varicella-zoster virus infection in pregnancy, 795
 acyclovir in, 281-283, 795
 laboratory tests for, 222-224
 placental findings in, 239
 pneumonia in, 283
 teratogenicity of, 248-249
- Vasculature
 congestion in, and chronic pelvic pain, 156-157, 160-162, 197
 dermal changes in pregnancy, 713-714, 730-731
- Vasoactive intestinal peptide, 125
- Vasopressin levels in dysmenorrhea, 169-170
- Venezuelan equine encephalitis virus infection in pregnancy, teratogenicity of, 250
- Venography in deep vein thrombosis in pregnancy, 474
- Venous compliance in twin gestation, 12
- Ventilator therapy in pregnancy
 in acute respiratory failure, 495-500
 in septic shock, 488-489
- Verapamil, hyperprolactinemia from, 625
- Vesicovaginal fistulas, 386-389
- Vestibule, pain in, 148
- Videocystourethrography, 311, 322-323, 395
- Villitis in virus infections, 234, 235-236
- Virilization in hyperandrogenism, 641
- Virus infections in pregnancy
 acyclovir in, 276-283
 laboratory tests for, 218-230
 placental findings in, 232-240
 review questions, 291
 skin lesions in, 792-794
 teratogenicity of, 242-250
 zidovudine in, 283-285
- Vulvovaginitis in pregnancy
 candidal, 732
 trichomonal, 732
- Weight gain in twin gestation, 10
- Zidovudine in AIDS in pregnancy, 283-285
- Zygosity determination in twin gestation, 70-71

Adams
Adash
Adelso
Albert
Alvare
Baker
Baker
Barbie
Bartel
Benirs
Bent,
Berek
Berko
Bicsak
Brown
Bruba
Burke
Carls
Casper
Catam
Cetru
Chan
Chate
Cherv
Cheun
Creas
Cuko
Cunn
Curti
Dacus
D'Al
Dasca
Dawo
DeLa
DePa
DePr
Dicki
Eudy
Faro
Gam
Goni
Hank
Hann
Haut
Haya
Heap
Helm
Herr
Hick
Hodg

AUTHOR INDEX

- Adams, Diana M., 52
 Adashi, Eli Y., 537, 622
 Adelson, Mark D., 801
 Albertson, Barry D., 591
 Alvarez, Manuel, 79
 Baker, David A., 217, 253, 258
 Baker, Glen F., 728
 Barbieri, Robert L., 640
 Bartelsmeyer, James A., 777
 Benirschke, Kurt, 18
 Bent, Alfred E., 358
 Berek, Jonathan S., 852
 Berkowitz, Richard, 79
 Bicsak, Thomas A., 690
 Brown, Zane A., 276
 Brubaker, Linda, 315
 Burke, M. Shannon, 69
 Carlson, John A., Jr., 910
 Casper, Robert F., 611
 Catanzarite, Val, 754
 Cetrulo, Curtis L., 32
 Chang, R. Jeffrey, 655
 Chatelain, Stephen M., 473
 Chervenak, Frank A., 52
 Cheung, Anthony P., 655
 Creasy, Robert K., 502
 Cukor, George, 218
 Cunningham, F. Gary, 406, 460
 Curtin, John P., 883
 Dacus, John V., 738
 D'Alton, Mary E., 42
 Dascal, Andre, 218
 Dawood, M. Yusoff, 168
 DeLancey, John O. L., 298
 DePaolo, Louis V., 690
 DePriest, P. D., 846
 Dickinson, Jan, 242
 Eudy, Sid F., 728
 Faro, Sebastian, 482, 792
 Gambone, Joseph C., 205
 Gonik, Bernard, 242
 Hankins, Gary D. V., 493, 759
 Hannigan, Edward V., 837
 Hauth, John C., 515
 Hayashi, Robert H., 746
 Heaps, James M., 852
 Helm, C. William, 863
 Hernandez, Cristela, 460, 526
 Hickok, Durlin E., 3
 Hodgen, Gary D., 551
 Holcomb, William L., Jr., 467
 Hollenbach, Kathryn A., 3
 Horowitz, Gary M., 759
 Jones, Howard W., III, 815, 826
 Jones, Johannes M., 32
 Kaplan, Cynthia, 232, 268
 Katz, Eugene, 622
 Kilgore, Larry C., 863
 LaBarbera, Andrew R., 576
 Labasky, Richard F., 382
 Lavery, J. Patrick, 414
 Leach, Gary E., 382
 Leveno, Kenneth J., 405
 Libman, Michael D., 218
 Ling, Nicholas, 690
 Lowe, Thomas William, 406, 454
 Mainprize, Thomas C., 308
 Martin, James N., Jr., 438
 Mattison, Donald R., 718
 McCaul, James F., IV, 438
 Mendelson, Jack, 218
 Mercer, Brian M., 42
 Morrow, C. Paul, 883
 Murphy, Ana A., 137
 Murray, Michael J., 889
 Nageotte, Michael P., 61
 Neifert, Marianne, 102
 Niermeyer, Susan, 88
 Norton, Peggy A., 293, 295, 325
 O'Brien, Timothy J., 713
 Orr, James W., Jr., 258
 Osborne, Newton G., 801
 Parmley, Tim, 713
 Patsner, Bruce, 258
 Pearlman, Mark, 482
 Petrie, Roy H., 467, 777
 Phelan, Jeffrey P., 432
 Photopulos, Guy J., 872
 Podratz, Karl C., 897
 Porreco, Richard P., 1
 Powell, D. E., 846
 Quirk, J. Gerald, Jr., 473, 711, 754
 Rapkin, Andrea J., 119
 Rebar, Robert W., 576
 Reiter, Robert C., 117, 130, 154, 179, 205
 Richardson, David A., 378
 Roseff, Scott J., 137
 Sand, Peter K., 315
 Sbarra, Anthony J., 32
 Scott, Richard T., Jr., 551

AUTHOR INDEX

Shimasaki, Shunichi, 690
Shmoys, Susan, 268
Slocumb, John C., 145, 196
Smith, Leon G., Jr., 792
Stanhope, C. Robert, 897
Stanton, Stuart L., 346
Stenchever, Morton A., 161
Stock, Richard J., 448
Stouffer, Richard L., 668
Strassner, Howard T., 782
Thorneycroft, Ian H., 563
Thorpe, John, 102
Tucker, J. Martin, 515
van Nagell, J. R., Jr., 846
Veldhuis, Johannes D., 538

Versi, Eboo, 392
Wall, L. Lewis, 367
Watts, D. Heather, 276
Webb, Maurice J., 897
Wendel, George D., 526
Wiesner, Mark G., 179
Wilkins, Isabelle, 502
Wilkinson, Edward J., 817
Wilson, P. Don, 330
Witt, Barry R., 563
Wong, Derek J., 782
Wood, Dennis Patrick, 179
Yeast, John D., 10
Yeomans, Edward R., 422
Zahn, Christopher M., 422

